Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Workability01:24

Factors Affecting Workability

The workability of concrete is a critical characteristic that influences the ease of mixing, handling, and finishing the concrete. It is affected by several factors including water content, aggregate properties, and admixtures like air entrainment. Water plays a fundamental role as it lubricates the concrete mix, facilitating easier movement and placement. However, the water requirement varies depending on the texture and shape of aggregates. Finer particles and angular, rough-textured...
Compacting Factor test01:22

Compacting Factor test

The compacting factor test is a method used to assess the workability of concrete. It is  especially suitable for concrete mixes containing aggregates up to one and a half inches in size. This test involves specialized equipment consisting of two truncated cone-shaped hoppers and a cylinder, all with polished interior surfaces to minimize friction.
The procedure begins by placing concrete into the upper hopper without any compaction. Once filled, the bottom door of this hopper is opened,...
Factors Affecting Activity Coefficient01:17

Factors Affecting Activity Coefficient

The extended Debye-Hückel equation indicates that the activity coefficient of an ion in an aqueous solution at 25°C depends on three partially interdependent properties: the ionic strength of the solution, the charge of the ion, and the ion size. 
The activity coefficient value for an ion is close to one when the solution has almost zero ionic strength, i.e., when the solution shows close to ideal behavior. As the ionic strength of the solution increases from 0 to 0.1 mol/L, a decrease in the...
Power Factor Correction01:20

Power Factor Correction

The power transmission to a factory involves the transfer of apparent power, a combination of active and reactive power. The power factor measures how effectively electrical power is converted into useful work output. The ratio of the real power (KW) that does the work to the apparent power (KVA) supplied to the circuit.
Bioreactor Controls-III01:22

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Methods of Medium Optimization01:28

Methods of Medium Optimization

Optimizing growth media enhances microbial proliferation and maximizes product yield. Statistical experimental design methodologies provide structured and reproducible approaches, offering progressively higher levels of robustness and efficiency.The One-Factor-at-a-Time (OFAT) MethodThe One-Factor-at-a-Time (OFAT) method involves adjusting a single variable while keeping all others constant. However, it cannot detect interactions between variables, often leading to suboptimal outcomes when...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generational advancement of factor VIIIa mimetics.

Blood·2026
Same author

Factor VIII <i>in vitro</i> bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.

Research and practice in thrombosis and haemostasis·2026
Same author

Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression.

Therapeutic advances in hematology·2026
Same author

Molecular genetic testing in von Willebrand disease: past, present, and beyond.

Haematologica·2026
Same author

Large deletions in the <i>F8</i> gene predict immune tolerance induction failure in people with severe hemophilia A.

Research and practice in thrombosis and haemostasis·2025
Same author

Von Willebrand factor and von Willebrand disease in ageing: mechanisms, evolving phenotypes, and clinical implications.

The Lancet. Haematology·2025
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

GENPLAT: an Automated Platform for Biomass Enzyme Discovery and Cocktail Optimization
11:38

GENPLAT: an Automated Platform for Biomass Enzyme Discovery and Cocktail Optimization

Published on: October 24, 2011

Improvements in factor concentrates.

David Lillicrap1

  • 1Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Kingston, Canada. lillicrap@cliff.path.queensu.ca

Current Opinion in Hematology
|July 9, 2010
PubMed
Summary
This summary is machine-generated.

New strategies are enhancing hemophilia concentrate therapies by extending clotting factor half-lives, reducing infusion frequency. Promising protein-engineering initiatives are advancing, with several novel treatments nearing clinical application.

More Related Videos

Twin-Screw Extrusion Process to Produce Renewable Fiberboards
07:21

Twin-Screw Extrusion Process to Produce Renewable Fiberboards

Published on: January 27, 2021

Related Experiment Videos

Last Updated: Jun 11, 2026

GENPLAT: an Automated Platform for Biomass Enzyme Discovery and Cocktail Optimization
11:38

GENPLAT: an Automated Platform for Biomass Enzyme Discovery and Cocktail Optimization

Published on: October 24, 2011

Twin-Screw Extrusion Process to Produce Renewable Fiberboards
07:21

Twin-Screw Extrusion Process to Produce Renewable Fiberboards

Published on: January 27, 2021

Area of Science:

  • Hematology
  • Protein Engineering
  • Pharmacology

Background:

  • Current hemophilia treatment relies on clotting factor concentrate infusions.
  • Prophylactic therapy significantly reduces musculoskeletal pathology compared to on-demand treatment.
  • Reducing infusion frequency is a key goal for improving patient adherence and outcomes.

Purpose of the Study:

  • To review innovative strategies for improving hemophilia concentrate therapies.
  • To highlight protein-engineering advancements in developing novel clotting factor concentrates.
  • To assess the progress of new hemophilia treatments in clinical trials.

Main Methods:

  • Review of recent protein-engineering initiatives for hemophilia therapy.
  • Evaluation of strategies to prolong clotting factor half-life.
  • Analysis of methods such as polymer conjugation and FcRn receptor recycling.

Main Results:

  • Significant progress in protein-engineering for hemophilia treatment over the past five years.
  • Novel concentrates aim to extend clotting factor half-life, reducing infusion frequency.
  • Strategies include hydrophilic polymer conjugation and FcRn receptor recycling fusion proteins.

Conclusions:

  • Development of extended half-life clotting factors shows encouraging progress.
  • Several novel hemophilia concentrate therapies are expected in the near future.
  • These advancements promise to enhance hemophilia management and patient care.